Mirabegron

米拉贝隆

Report date: 2026/05/24 20:00:34
NMEFirst In Class

Base Information

Drug NameMirabegron
Drug Alias Namemirabegronum米雷勃隆Betmiga贝坦利Myrbetriq +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta-3 adrenergic receptor agonists
TargetsBeta-3 adrenergic receptor
Therapy Area/IndicationsCognition DisordersLower Urinary Tract SymptomsUrological Manifestations +[30] 
Global Approved IndicationsUrinary Bladder, Overactive
Approved Indications in ChinaUrinary Bladder, Overactive
Original Approved Country/TerritoryJapan
Original Approved Date2011/07/01
Country/TerritoryCzechiaBelgiumArmenia +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GoettingenQingdao Baheal Medical IncUniversity of Athens +[15] 
Inactive CompaniesAstellas Scientific & Medical Affairs IncGenuine Research Center, EgyptAstellas Pharma Us Inc +[14] 
Active IndicationsLower Urinary Tract SymptomsObesityPrediabetic State +[11] 
Inactive IndicationsCognition DisordersUrological ManifestationsPain +[19] 

Other Information

ATC CodeG04BD12
Related LinksWikipediaDrugBankKEGG